Inozyme Pharma (NASDAQ:INZY) Announces Quarterly Earnings Results

Inozyme Pharma (NASDAQ:INZY) issued its quarterly earnings data on Monday. The company reported ($0.42) EPS for the quarter, hitting the consensus estimate of ($0.42), Zacks reports.

Inozyme Pharma Stock Performance

Shares of NASDAQ INZY opened at $1.13 on Monday. The company has a quick ratio of 7.68, a current ratio of 7.68 and a debt-to-equity ratio of 0.51. The firm’s 50-day moving average price is $1.62 and its 200-day moving average price is $3.36. Inozyme Pharma has a 52-week low of $1.04 and a 52-week high of $7.80. The company has a market cap of $72.59 million, a PE ratio of -0.72 and a beta of 1.32.

Analyst Ratings Changes

INZY has been the subject of several recent research reports. Raymond James started coverage on Inozyme Pharma in a research report on Thursday, December 12th. They set an “outperform” rating and a $26.00 price objective for the company. Piper Sandler cut their price objective on shares of Inozyme Pharma from $43.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, January 13th. HC Wainwright boosted their price target on Inozyme Pharma from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, January 10th. Wedbush reiterated an “outperform” rating and set a $12.00 price objective on shares of Inozyme Pharma in a research note on Friday, January 10th. Finally, Wells Fargo & Company lowered their price target on Inozyme Pharma from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, January 13th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $18.33.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.